Eli Lilly filed six lawsuits on 12 August 2026 against US entities selling black-market retatrutide, an investigational molecule in Phase 3 trials that no regulator has approved for human use. The defendants are Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide: compounding pharmacies, medical spas and online sellers that Lilly says market products as “research use only” while intending them for human use. Lilly said it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general and licensing boards, and reported over 14,000 retatrutide listings across more than 100 countries.
